NICE/NPSA Issues Patient Safety Solution Guidance To Reduce The Risk Of Pneumonia In Patients On A Ventilator

The National Institute for Health and Clinical Excellence (NICE) in collaboration with the National Patient Safety Agency (NPSA) has issued guidance to improve the safety of patients in the NHS in England and Wales by reducing the risk of pneumonia in patients aged 16 years and older who are on a ventilator. Pneumonia is an inflammatory condition of the lungs caused by bacterial, viral or fungal infection.
(more...)


Simple Antibiotics For Pneumonia Are Best To Avoid Super Bugs, Says Researcher

Australian hospitals should avoid prescribing expensive broad-spectrum antibiotics for pneumonia to avoid the development of more drug-resistant super bugs, according to a University of Melbourne study.
(more...)


Variations Of Rare Lung Disease Examined

Lymphangioleiomyomatosis, or LAM, is a rare but serious lung disease that may cause severe respiratory symptoms in patients. The often-fatal disease has no cure.
(more...)


Study Shows Traditional Chinese Medicine Of Qigong Therapy As A Potential Complementary Treatment For Patients Suffering From Osteoarthritis

Qigong therapy, a form of traditional Chinese medical practice, appears to be a potential complementary treatment for osteoarthritis dependent upon the capability of the healer, according to a study conducted at University of Medicine and Dentistry of New Jersey by Kevin Chen, PhD, MPH, and Dr. Adam Perlman, MPH, FACP. The study, titled "Effects of external Qigong therapy on osteoarthritis of the knee," was published in the April 2008 edition of Clinical Rheumatology.
(more...)


Novavax Announces Favourable Results From Phase I/Iia PANDEMIC Influenza Vaccine Program

Novavax, Inc. (NASDAQ: NVAX) announced favorable results from the second stage of the Phase I/IIa human clinical trial of its pandemic influenza virus-like particle (VLP) vaccine candidate. The vaccine, which does not contain an adjuvant, induced robust neutralizing antibody responses. Novavax's VLP candidate is directed against the H5N1 A/Indonesia/05/2005 avian influenza strain.
(more...)


JAMA Publishes Study Results On Efficacy Of The Bard Agento(R) I.C. Silver-Coated Endotracheal Tube In Preventing Ventilator-Associated Pneumonia

C. R. Bard, Inc. (NYSE: BCR) announced the publication of the North American Silver-Coated Endotracheal Tube (NASCENT) clinical study results in the August 20, 2008 edition of the Journal of the American Medical Association (JAMA). The NASCENT study - which enrolled 2,003 patients in 54 hospitals - evaluated the efficacy of the Agento® I.C. silver-coated endotracheal tube (ETT) in the reduction of microbiologically confirmed ventilator-associated pneumonia (VAP). The U.S.
(more...)


High Levels Of Metals Found In Ayurvedic Medicines Purchased On The Internet

A study published in the August 27 issue of JAMA finds that of several Ayurvedic medicines purchased on the Internet, about 20% have unacceptably high levels of lead, mercury, or arsenic. Ayurvedic medicines - based on a traditional medical system commonly used in India - are employed by a majority of India's 1.1 billion population as well as peoples from South Asia and other localities. Robert B. Saper, M.D., M.P.H.
(more...)


Pitt Scientists Receive $3.6 Million To Test Vaccine Against Deadliest Strain Of Avian Flu

Scientists at the University of Pittsburgh Center for Vaccine Research have been awarded $3.6 million from the National Institutes of Health to conduct animal studies of vaccines designed to protect against the most common and deadliest strain of avian flu, H5N1. Recent outbreaks of H5N1 have prompted health officials to warn of its continued threat to global health and potential to trigger an avian flu pandemic.
(more...)


Fraud Discovery Institute Retracts Herbalife Accusations - California

Herbalife Ltd. (NYSE: HLF) and the Fraud Discovery Institute announced that the Fraud Discovery Institute retracts its accusations against multi-level marketer Herbalife. Herbalife and the Fraud Discovery Institute reached the agreement to avoid litigation.
(more...)


Novel Technology Could Transform Production Of Flu Vaccine With Enhanced Potency, Manufacturing Capacity And Cost-Effectiveness

VaxInnate Corporation announced that its M2e universal influenza vaccine candidate was safe and immunogenic in its first Phase I clinical trial, raising hopes for a universal influenza vaccine that could provide protection against seasonal and pandemic influenza strains.
(more...)